SecBot SecBot
SECBOTREPLAY Home › Report › COGT

COGT · Cogent Biosciences reported updated Phase 2 APEX trial results for…

Cogent Biosciences, Inc. · PRESS-RELEASE filed Jun 12, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 12, 2026 at 08:00 ET

Cogent Biosciences reported updated Phase 2 APEX trial results for bezuclastinib in advanced systemic mastocytosis (AdvSM) at EHA 2026, showing a 65% objective response rate per mIWG criteria and 81% per PPR criteria, with 91% of patients achieving ≥50% reduction in KIT D816V variant allele frequency. The company plans to submit an NDA in June 2026 and expects commercial launch later this year.

  • Updated APEX trial data: 65% ORR per mIWG criteria (CR+CRh+PR+CI) and 81% ORR per PPR criteria in AdvSM patients.
  • 91% of patients achieved ≥50% reduction in KIT D816V variant allele frequency; 89% had ≥50% reduction in bone marrow mast cells or clearance of aggregates.
  • 12-month PFS rate of 79% and 12-month OS rate of 87%.
  • NDA submission for bezuclastinib in AdvSM planned for June 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access